Description

Trimethoxy resveratrol is a resveratrol prodrug designed to improve bioavailability of the parent compound; it appears to display antioxidative and anti-inflammatory properties like resveratrol. Trimethoxy resveratrol displays stronger anticancer chemotherapeutic and chemopreventive activities than resveratrol. In an in vitro model of prostate cancer, this compound induced apoptosis and expanded the SG2/M phase in p53 null cells. In animal models with prostate cancer xenografts, trimethoxy resveratrol decreased tumor volume and growth.